WO2000029582A3 - Cell surface receptor antigen vaccines - Google Patents
Cell surface receptor antigen vaccines Download PDFInfo
- Publication number
- WO2000029582A3 WO2000029582A3 PCT/US1999/027404 US9927404W WO0029582A3 WO 2000029582 A3 WO2000029582 A3 WO 2000029582A3 US 9927404 W US9927404 W US 9927404W WO 0029582 A3 WO0029582 A3 WO 0029582A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell surface
- surface receptor
- receptor antigen
- vaccines
- antigen vaccines
- Prior art date
Links
- 108010001857 Cell Surface Receptors Proteins 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000006240 membrane receptors Human genes 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99965005A EP1131432A2 (en) | 1998-11-18 | 1999-11-17 | Cell surface receptor antigen vaccines |
CA002351729A CA2351729A1 (en) | 1998-11-18 | 1999-11-17 | Cell surface receptor antigen vaccines |
JP2000582565A JP2002530294A (en) | 1998-11-18 | 1999-11-17 | Cell surface receptor antigen vaccine |
AU31015/00A AU3101500A (en) | 1998-11-18 | 1999-11-17 | Surface receptor antigen vaccines |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10910698P | 1998-11-18 | 1998-11-18 | |
US60/109,106 | 1998-11-18 | ||
US09/441,411 US6734172B2 (en) | 1998-11-18 | 1999-11-16 | Surface receptor antigen vaccines |
US09/441,411 | 1999-11-16 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000029582A2 WO2000029582A2 (en) | 2000-05-25 |
WO2000029582A3 true WO2000029582A3 (en) | 2000-10-12 |
WO2000029582A8 WO2000029582A8 (en) | 2001-03-01 |
Family
ID=26806620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027404 WO2000029582A2 (en) | 1998-11-18 | 1999-11-17 | Cell surface receptor antigen vaccines |
Country Status (5)
Country | Link |
---|---|
US (2) | US6734172B2 (en) |
EP (1) | EP1131432A2 (en) |
JP (1) | JP2002530294A (en) |
CA (1) | CA2351729A1 (en) |
WO (1) | WO2000029582A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7815920B2 (en) | 1998-09-21 | 2010-10-19 | Allergy Therapeutics (UK) Ltd | Method of preparing an antigen-containing formulation |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
US7198920B1 (en) * | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
ES2629683T3 (en) | 1999-11-30 | 2017-08-14 | Mayo Foundation For Medical Education And Research | B7-H1, a new immunoregulatory molecule |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
US20030148468A1 (en) * | 2000-07-24 | 2003-08-07 | Seishi Kato | Method of preparing antibody by gene immunization |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
ATE490267T1 (en) * | 2001-06-05 | 2010-12-15 | Curevac Gmbh | STABILIZED MRNA WITH INCREASED G/C CONTENT CODING A VIRAL ANTIGEN |
AU2002322211A1 (en) * | 2001-07-12 | 2003-01-29 | Canvac | Methods and compisitions for activation human t cells in vitro |
ES2328025T3 (en) | 2001-10-09 | 2009-11-06 | Mayo Foundation For Medical Education And Research | IMPROVEMENT OF IMMUNE RESPONSES BY AGONIST ANTIBODIES 4-1 BB. |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
AU2004315509A1 (en) * | 2003-12-05 | 2005-08-18 | Becton, Dickinson And Company | Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
CA2943949C (en) | 2004-10-06 | 2020-03-31 | Mayo Foundation For Medical Education And Research | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
US7316789B2 (en) * | 2004-11-02 | 2008-01-08 | International Business Machines Corporation | Conducting liquid crystal polymer nature comprising carbon nanotubes, use thereof and method of fabrication |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
AU2007354917B2 (en) | 2006-09-26 | 2013-06-06 | Access To Advanced Health Institute | Vaccine composition containing synthetic adjuvant |
EP3061462B1 (en) | 2007-07-02 | 2019-02-27 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US8703416B2 (en) | 2008-07-17 | 2014-04-22 | Somalogic, Inc. | Method for purification and identification of sperm cells |
CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
EP2480771B1 (en) | 2009-09-23 | 2015-04-15 | Aerojet Rocketdyne of DE, Inc. | A system and method of combustion for sustaining a continuous detonation wave with transient plasma |
EP2542266A4 (en) | 2010-03-03 | 2013-10-23 | Somalogic Inc | Aptamers to 4-1bb and their use in treating diseases and disorders |
SG2014006522A (en) | 2010-04-12 | 2014-03-28 | Somalogic Inc | 5-position modified pyrimidines and their use |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP2804624B1 (en) | 2012-01-19 | 2018-12-26 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
TR201908003T4 (en) | 2012-02-07 | 2019-06-21 | Infectious Disease Res Inst | Advanced adjuvant formulations containing TLR4 agonists and their method of use. |
SI2850431T1 (en) | 2012-05-16 | 2018-08-31 | Immune Design Corp. | Vaccines for hsv-2 |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EA032326B1 (en) | 2013-04-18 | 2019-05-31 | Иммьюн Дизайн Корп. | Gla monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
WO2015050663A1 (en) | 2013-10-01 | 2015-04-09 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of bim |
ES2806575T3 (en) | 2013-11-01 | 2021-02-18 | Curevac Ag | Modified RNA with decreased immunostimulatory properties |
BR112016015422A2 (en) | 2013-12-31 | 2017-10-24 | Infectious Disease Res Inst | single vial vaccine formulations |
KR101576728B1 (en) * | 2014-03-06 | 2015-12-10 | 가톨릭대학교 산학협력단 | Immune cell vaccine and use thereof |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
WO2016007499A1 (en) * | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
CN113456812A (en) | 2015-01-09 | 2021-10-01 | 埃图比克斯公司 | Methods and compositions for combination immunotherapy |
JP2018502922A (en) | 2015-01-09 | 2018-02-01 | イーチュービクス コーポレイション | Methods and compositions for Ebola virus vaccination |
RU2714157C2 (en) * | 2015-02-06 | 2020-02-12 | Хит Байолоджикс, Инк. | Vector, co-expressing molecules for vaccination and costimulatory molecules |
EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
US11464839B2 (en) | 2015-12-04 | 2022-10-11 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different MHC molecules |
CN108697779B (en) | 2016-01-07 | 2023-09-19 | 杜克大学 | Cancer vaccine and delivery method |
EP4112638A1 (en) | 2016-05-16 | 2023-01-04 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
CN109195587A (en) | 2016-06-01 | 2019-01-11 | 传染病研究所 | Nanometer pellet alum containing cementing agent |
US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
US20200276299A1 (en) | 2017-09-08 | 2020-09-03 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
WO2020243115A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920003787B1 (en) | 1990-03-05 | 1992-05-14 | 한국과학기술 연구원 | Method for producing igf-i |
US5596090A (en) | 1992-07-24 | 1997-01-21 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human VCAM-1 RNA |
US5571711A (en) | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
EP0668350B2 (en) | 1994-02-16 | 2008-12-03 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma |
US5821122A (en) | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
JPH0975090A (en) | 1995-09-13 | 1997-03-25 | Kanegafuchi Chem Ind Co Ltd | Member for adhering cell |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
US6348450B1 (en) * | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
-
1999
- 1999-11-16 US US09/441,411 patent/US6734172B2/en not_active Expired - Fee Related
- 1999-11-17 CA CA002351729A patent/CA2351729A1/en not_active Abandoned
- 1999-11-17 EP EP99965005A patent/EP1131432A2/en not_active Withdrawn
- 1999-11-17 JP JP2000582565A patent/JP2002530294A/en not_active Withdrawn
- 1999-11-17 WO PCT/US1999/027404 patent/WO2000029582A2/en active Application Filing
-
2004
- 2004-01-20 US US10/762,128 patent/US7547681B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
Non-Patent Citations (7)
Title |
---|
BUONAVISTA N ET AL: "DNA immunization with a combination of rat neu antigen, CD86, and 4-1BB ligand results in the generation of HER-2/neu (HER-2) antibodies in neu transgenic mice.", SEVENTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER;SAN DIEGO, CALIFORNIA, USA; NOVEMBER 19-21, 1998, vol. 5, no. 6 CONF. SUPPL., November 1998 (1998-11-01), Cancer Gene Therapy Nov.-Dec., 1998, pages S2, XP000914673, ISSN: 0929-1903 * |
EMITAGE PETER C R ET AL: "Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2.", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH NOV., 1998, vol. 18, no. 11, November 1998 (1998-11-01), pages 927 - 937, XP000914693, ISSN: 1079-9907 * |
HELLSTROM INGEGERD ET AL: "T cell immunity to tumor antigens.", CRITICAL REVIEWS IN IMMUNOLOGY 1998, vol. 18, no. 1-2, 1998, pages 1 - 6, XP000914694, ISSN: 1040-8401 * |
KIM J J ET AL: "Development of a multicomponent candidate vaccine for HIV-1", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 879 - 883, XP004075675, ISSN: 0264-410X * |
LI YIWEN ET AL: "Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors.", JOURNAL OF EXPERIMENTAL MEDICINE 1996, vol. 183, no. 2, 1996, pages 639 - 644, XP000914698, ISSN: 0022-1007 * |
MELERO IGNACIO ET AL: "Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway.", EUROPEAN JOURNAL OF IMMUNOLOGY MARCH, 1998, vol. 28, no. 3, March 1998 (1998-03-01), pages 1116 - 1121, XP000914703, ISSN: 0014-2980 * |
ZITVOGEL L. ET AL: "interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors", EUR. J. IMMUNOL, vol. 26, 1996, pages 1335 - 1341, XP000914702 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7815920B2 (en) | 1998-09-21 | 2010-10-19 | Allergy Therapeutics (UK) Ltd | Method of preparing an antigen-containing formulation |
Also Published As
Publication number | Publication date |
---|---|
US7547681B2 (en) | 2009-06-16 |
CA2351729A1 (en) | 2000-05-25 |
US20030008342A1 (en) | 2003-01-09 |
EP1131432A2 (en) | 2001-09-12 |
US20040219161A1 (en) | 2004-11-04 |
JP2002530294A (en) | 2002-09-17 |
US6734172B2 (en) | 2004-05-11 |
WO2000029582A2 (en) | 2000-05-25 |
WO2000029582A8 (en) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000029582A8 (en) | Cell surface receptor antigen vaccines | |
DE60234375D1 (en) | PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE | |
NZ506086A (en) | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins, antigens comprising derivatised thiol residues and of compositions for vaccination | |
DK0979284T4 (en) | Vaccination reagents that induce a CD8 T cell immune response | |
WO2005066204A3 (en) | Neutralizing epitope-based growth enhancing vaccine | |
WO2002080851A3 (en) | Chimeric vaccines | |
EP0278940A3 (en) | Hepatitis b virus surface antigens and hybrid antigens containing them | |
WO2003024480A3 (en) | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles | |
EP1716173B8 (en) | Carcinoembryonic antigen fusion protein and uses thereof | |
WO2002012281A3 (en) | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen | |
NO20061203L (en) | Method and composition for reconstituting multiepitopic antigens to initiate an immune response | |
WO1989001973A3 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
WO2001029233A3 (en) | Chimeric immunogenic compositions and nucleic acids encoding them | |
WO1996017936A3 (en) | Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease | |
WO2005012537A3 (en) | Adenoviral vector-based vaccines | |
WO2004026265A3 (en) | Compositions and methods for treatment of herpesvirus infections | |
WO2000025722A3 (en) | ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS | |
ATE73349T1 (en) | HEPATITIS SURFACE ANTIGEN PARTICLE VACCINATION. | |
WO2000063385A3 (en) | Nucleic acid immunization | |
EP0972054A4 (en) | Enhancement of immune response using targeting molecules | |
DE602005010680D1 (en) | COMPOSITIONS AND METHOD FOR INDUCING AN ANTITUMORIMMUNITY | |
WO2002051237A3 (en) | Helicobacter proteins, nucleic acids and uses thereof | |
WO2000006742A3 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
WO2000063242A8 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
WO2001035993A3 (en) | Compositions and methods for stimulating an immune response against infectious agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 21/2000 UNDER (30) REPLACE "NOT FURNISHED" BY "09/441411" |
|
ENP | Entry into the national phase |
Ref document number: 2351729 Country of ref document: CA Kind code of ref document: A Ref document number: 2351729 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2000 582565 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/005023 Country of ref document: MX Ref document number: 1999965005 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999965005 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |